Zotepine

Research use only, not for human use.

Zotepine, an antipsychotic agent, is a potent antagonist of 5-HT2A, 5-HT2C, Histamine H1, α1-adrenergic, and Dopamine D2 receptors, with Kds of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM, and 8 nM, respectively.

Zotepine, an antipsychotic agent, is a potent antagonist of 5-HT2A, 5-HT2C, Histamine H1, α1-adrenergic, and Dopamine D2 receptors, with Kds of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM, and 8 nM, respectively. Zotepine is a second-generation antipsychotic with a primary use as a treatment for schizophrenia, although clinical trials have been conducted into its efficacy as an antimanic agent in patients with acute bipolar mania.

Zotepine shows multiple antagonistic profiles with strong affinities to α1-adrenergic, α2-adrenergic, Dopamine D2, Histamine H1, Muscarinic, 5-HT1A, 5-HT1D, 5-HT2A, and 5-HT2C receptors, with Kds of 7.3, 180, 8, 3.3, 330, 280, 80, 2.6, 3.2 nM, respectively.

Zotepine (1-3 mg/kg; a single i.p.) dose-dependently increases noradrenaline, dopamine, GABA, and glutamate release without affecting 5-HT levels in the medial prefrontal cortex of rats. Animal Model:Male Sprague-Dawley rats (250-300 g)Dosage:1, 3 mg/kg Administration:A single i.p.Result:Increased noradrenaline, dopamine, GABA, and glutamate release without affecting 5-HT levels in the medial prefrontal cortex.Increased neuronal firing frequencies in the VTA, DRN, LC and MTN in a dose-dependent manner.

——

GPCR/G Protein

Dopamine Receptor

Gpx4

——

——

26615-21-4

331.86

C18H18ClNOS

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (75.33 mM)

CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12

——

(-20℃)

With Ice Pack

≥ 2 years